With over 35 new FDA-approved indications since the second edition-featuring groundbreaking advancements such as CAR-T therapy-this handbook serves as a quick reference for practice-changing information on complex diagnostic dilemmas, frontline treatments, refractory scenarios, and relapse management.
Key Features:
- New chapters on precursor states in myeloid malignancies (CHIP/CCUS), familial/inherited risks of hematologic malignancies, CAR-T versus Bispecific Treatment, and mechanisms of CAR-T resistance.
- Entirely new board-style questions, enhancing critical thinking and knowledge application with every clinical chapter.
- Features updated chapters that concisely outline new standards of care and management considerations, accompanied by key references for further reading.
- Highlights essential diagnostic tools, including updated 2022 WHO and ICC classification systems, that aid in conducting critical differential diagnoses and resolving complex diagnostic dilemmas.
- Delivers key updates on potential practice-changing clinical trials and paradigm-shifting treatment considerations within each disease-based chapter, ensuring clinicians stay at the forefront of hematologic oncology.
Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, D ausgeliefert werden.








